24.3 C
New York
Wednesday, June 3, 2026

Tag: biopsy

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

Caris Life Sciences Reports Second Quarter 2025 Financial Results

IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results...

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiopsy